Would the incorporation of CellPryme-M into the manufacturing of an already approved (or clinically advanced) cell therapy product send that product back to phase 1 clinical trials?
If so, CellPryme-M may only be attractive to pre-clinical or phase 1 assets.
Anyone able to answer this question? If not, I'll email the company.
CellPryme-M question
Add PTX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.3¢ |
Change
-0.001(2.27%) |
Mkt cap ! $34.62M | |||
| Open | High | Low | Value | Volume |
| 4.3¢ | 4.5¢ | 4.3¢ | $17.99K | 416.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 152502 | 4.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.5¢ | 502504 | 5 |
View Market Depth
| Last trade - 15.59pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
4.3¢ |
Change
-0.001 ( 4.44 %) |
||||
| Open | High | Low | Volume | ||
| 4.3¢ | 4.5¢ | 4.3¢ | 123400 | ||
| Last updated 15.57pm 17/05/2024 ? | |||||
| PTX (ASX) Chart |